Classifications: antithrombotic agent; antiplatelet antibody; platelet glycoprotein (gp iib/iiia) inhibitor; (gp iib/iiia) inhibitor; Therapeutic:antiplatelet; platelet (gp iib/iiia) inhibitor
Pregnancy Category: B
0.75 mg/mL, 2 mg/mL injection
Binds to the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor sites of platelets.
Inhibits platelet aggregation by preventing fibrinogen, von Willebrand's factor, and other molecules from adhering to GPIIb/IIIa
receptor sites on platelets.
Treatment of acute coronary syndromes (unstable angina, non-Q-wave MI) and patients undergoing percutaneous coronary interventions
Hypersensitivity to eptifibatide; active bleeding; GI or GU bleeding within 6 wk; thrombocytopenia; renal failure requiring
dialysis; coagulopathy; recent major surgery or trauma; intracranial neoplasm, intracranial bleeding within 6 mo; concurrent
administration of another GPIIb/IIIa receptor inhibitor (e.g., abciximab); severe hypertension (systolic blood pressure >200
mm Hg or diastolic blood pressure >110 mm Hg), aneurysm.
Hypersensitivity to related compounds (e.g., abciximab, tirofiban, lamifiban); concurrent administration of other anticoagulants;
pregnancy (category B), lactation. Safety and effectiveness in children are not established.
Route & Dosage
|Acute Coronary Syndromes (ACS)
Adult: IV 180 mcg/kg initial bolus (max: 22.6 mg) followed by 2 mcg/kg/min until hospital discharge or up to 72 h
Percutaneous Coronary Interventions (PCI)
Adult: IV 180 mcg/kg initial bolus followed by 2 mcg/kg/min; after 10 min, a second 180 mcg/kg bolus should be given; the infusion should
continue up to 24 h after the end of the procedure
If Clcr 1049 mL/min, then give 1 mcg/kg/min continuous infusion.
- Note: Review contraindications to administration prior to giving this drug.
PREPARE: Direct: Give undiluted.
ADMINISTER: Direct: Give bolus doses IV push over 12. Continuous: Start continuous infusion immediately following bolus dose. Give undiluted directly from the 100-mL vial (at a rate based
on patient's weight) using a vented infusion set. May be given in the same IV line with NS or D5/NS (either solution may contain
up to 60 mEq KCl).
- Store unopened vials at 2°8° C (36°46° F) and protect from light. Discard any unused portion
in opened vial.
Adverse Effects (≥1%)CNS:
Intracranial bleed (rare). GI:
GI bleeding. Hematologic: Bleeding
(major bleeding 4.411%), anemia
InteractionsDrug: oral anticoagulants
, dipyridamole, ticlopidine, dextran
may increase risk of bleeding.
68 h after stopping infusion. Metabolism:
Minimally metabolized. Elimination:
50% in urine. Half-Life:
Assessment & Drug Effects
- Lab tests: Prior to infusion determine PT/aPTT & INR, ACT for those undergoing percutaneous coronary intervention (PCI); Hct
or Hgb; platelet count; and serum creatinine.
- Lab tests: Monitor aPTT & INR (target aPPT, 5070 s); during PCI (target ACT, 300350 s).
- Minimize all vascular and other trauma during treatment. When obtaining IV access, avoid using a noncompressible site such
as the subclavian vein.
- Monitor carefully for and immediately report S&S of bleeding (e.g., femoral artery access site bleeding, intracerebral hemorrhage,
- Immediately stop infusion of eptifibatide and heparin if bleeding at the arterial access site cannot be controlled by pressure.
- Achieve hemostasis at the arterial access site by standard compression for a minimum of 4 h prior to hospital discharge following
discontinuation of eptifibatide and heparin.